NCT04494412 - An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Influenza, HumanArthralgia

Interventions

DRUG

Zanamivir

Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.

Trial Locations (9)

20122

RECRUITING

GSK Investigational Site, Milan

28046

RECRUITING

GSK Investigational Site, Madrid

50139

RECRUITING

GSK Investigational Site, Florence

Unknown

RECRUITING

GSK Investigational Site, Messina

00165

RECRUITING

GSK Investigational Site, Roma

85-168

COMPLETED

GSK Investigational Site, Bydgoszcz

08950

RECRUITING

GSK Investigational Site, Barcelona

SW17 0QT

RECRUITING

GSK Investigational Site, London

W2 1NY

RECRUITING

GSK Investigational Site, London